Intraoperative cytokine adsorption in cardiothoracic transplant patients: An Australian propensity‐score matched pilot study

Abstract

AbstractBackgroundIt is unclear if immunomodulation via cytokine adsorption (CA) to reduce perioperative inflammatory cascade in cardiothoracic transplants is associated with better outcomes.ObjectiveThis pilot study aims to assess the clinical outcomes of intraoperative CA in heart/lung transplantation.MethodsFrom July to October 2020, intraoperative CA was instituted in 11 patients who underwent heart/lung transplantation. One‐to‐one propensity score matching without replacement was conducted with historical patients who did not receive CA at the time of surgery. Primary end‐points evaluated were vasopressor/ inotropic demands, blood loss and mortality. Secondary end‐points measured were operative morbidities.ResultsAfter matching, there were 2 (18.2%) ventricular assist device explant with heart transplantation, 2 (18.2%) heart transplantation and 7 (63.6%) lung transplantation in each group. Mean age in both groups were 53.3 years and 54.9 years respectively.The duration of noradrenaline requirement in the CA group was shorter (median, 1627 versus 3144 min, P = 0.5) and postoperative dopamine demand was significantly higher (median peak dose, 5.0 versus 0 μg/kg/min, P = 1.0; median duration of use, 7729 versus 0 min, P = 0.01). Non‐red blood cell transfusion rate was two times higher in CA patients (90.9% versus 45.4%, P = 0.06). Early mortality was higher in the control group (18.2% versus 9.1%, P = 1.0).No differences were observed in the incidences of operative morbidities.ConclusionIntraoperative CA in heart and lung transplantation in our institution was not associated with significant improvement in clinical outcomes, including vasopressor/inotropic demand. Larger studies are required to evaluate the transfusion requirements and mortality risks with CA use in this patient population.